AIM ImmunoTech: Difference between revisions
Brainulator9 (talk | contribs) m general fixes |
Joe Bacchus (talk | contribs) No edit summary |
||
| Line 58: | Line 58: | ||
}} |
}} |
||
'''Hemispherx Biopharma Inc.''' ({{AMEX|HEB}}) is a [[biopharmaceutical]] company based in [[New Brunswick, New Jersey|New Brunswick]], [[New Jersey|NJ]].<ref>{{cite news|first=Herb |last=Greenberg |title=Battle Royale Brewing: Hemispherx Biopharma and Asensio Tangle |url=http://www.thestreet.com/story/19841/battle-royale-brewing-hemispherx-biopharma-and-asensio-tangle.html |work=[[TheStreet.com]] |date=1998-09-18 |accessdate=24 August 2009 |archiveurl=https://www.webcitation.org/5jGEgdsC1?url=http://www.thestreet.com/story/19841/battle-royale-brewing-hemispherx-biopharma-and-asensio-tangle.html |archivedate=24 August 2009 |url-status=dead }}</ref> Founded in 1990, the company has 32 employees.<ref>{{cite web |title=Hemispherx Biopharma, Inc. |url=http://investing.businessweek.com/businessweek/research/stocks/snapshot/snapshot.asp?bridgesymbol=US;HEB |work=[[BusinessWeek]] |accessdate=24 August 2009 |archiveurl=https://www.webcitation.org/5jGEjmLcD?url=http://investing.businessweek.com/businessweek/research/stocks/snapshot/snapshot.asp?bridgesymbol=US;HEB |archivedate=24 August 2009 |url-status=dead }}</ref> |
'''Hemispherx Biopharma Inc.''' ({{AMEX|HEB}}) - known as AIM ImmunoTech Inc. since September 2019 - is a [[biopharmaceutical]] company based in [[New Brunswick, New Jersey|New Brunswick]], [[New Jersey|NJ]].<ref>{{cite news|first=Herb |last=Greenberg |title=Battle Royale Brewing: Hemispherx Biopharma and Asensio Tangle |url=http://www.thestreet.com/story/19841/battle-royale-brewing-hemispherx-biopharma-and-asensio-tangle.html |work=[[TheStreet.com]] |date=1998-09-18 |accessdate=24 August 2009 |archiveurl=https://www.webcitation.org/5jGEgdsC1?url=http://www.thestreet.com/story/19841/battle-royale-brewing-hemispherx-biopharma-and-asensio-tangle.html |archivedate=24 August 2009 |url-status=dead }}</ref> Founded in 1990, the company has 32 employees.<ref>{{cite web |title=Hemispherx Biopharma, Inc. |url=http://investing.businessweek.com/businessweek/research/stocks/snapshot/snapshot.asp?bridgesymbol=US;HEB |work=[[BusinessWeek]] |accessdate=24 August 2009 |archiveurl=https://www.webcitation.org/5jGEjmLcD?url=http://investing.businessweek.com/businessweek/research/stocks/snapshot/snapshot.asp?bridgesymbol=US;HEB |archivedate=24 August 2009 |url-status=dead }}</ref> |
||
== Pre-2019 == |
== Pre-2019 == |
||
Revision as of 16:33, 22 January 2020
 Hemispherx Biopharma Inc. company logo. | |
| Hemispherx | |
| AMEX: HEB | |
| Industry | Biopharmaceutical |
| Headquarters | , |
Key people | CEO Thomas K. Equels, M.S. J.D. CMO David R. Strayer, M.D. |
| Products | Ampligen® Alferon® |
| Services | Cancer Research |
| Total assets | $ 15.965 million  (2019[1]) |
Hemispherx Biopharma Inc. (AMEX: HEB) - known as AIM ImmunoTech Inc. since September 2019 - is a biopharmaceutical company based in New Brunswick, NJ.[2] Founded in 1990, the company has 32 employees.[3]
Pre-2019
The company has created an immunomodulatory double stranded RNA drug called Ampligen.[4] The company is developing Ampligen to use as a treatment for multiple cancer tumor types and for chronic fatigue syndrome.[5]
On April 3, 2001, Hemispherx Biopharma, Inc. adjusted and restated its 1999 financial statements to reflect charges relating to an extension of the exercise period to certain warrants as of February 1999.
On April 3, 2006, Hemispherx Biopharma, Inc. restated financial results for 2003 and 2004 due to accounting mistakes related to debentures and warrants issued between March 2003 and August 2005.[6]
In June, 2018, Hemispherx announced that Ampligen had shown effectiveness in activating the TLR3 without triggering T-cell regulatory activities, offering a potentially effective way to treat tumors.[7]
2019 Onward
As of June, 2019 Hemispherx is operating 5 studies examining the viability of Ampligen for combating Ovarian Cancer, to which end it has also raised tens of millions of dollars in shareholder capital.[8]
References
- ^ SEC Filings
- ^ Greenberg, Herb (1998-09-18). "Battle Royale Brewing: Hemispherx Biopharma and Asensio Tangle". TheStreet.com. Archived from the original on 24 August 2009. Retrieved 24 August 2009.
- ^ "Hemispherx Biopharma, Inc". BusinessWeek. Archived from the original on 24 August 2009. Retrieved 24 August 2009.
- ^ "Hemispherx licensed for chemical compound". Philadelphia Business Journal. 2006-08-29. Archived from the original on 24 August 2009. Retrieved 24 August 2009.
- ^ "Hemispherx Biopharma Inc. (use of Ampligen for chronic fatigue syndrome)". Philadelphia Business Journal. 2000-10-06. Retrieved 24 August 2009.
- ^ "Hemispherx delays 2005 statement".
- ^ "Hemispherx Biopharma (HEB) Highlights New Data Showing Ampligen's Positive Role in Reprograming Tumor Microenvironment". Street Insider. 5 June 2018.
- ^ Hemispherx Reports 2019 First Quarter Financial Results